Targeting the CD47-SIRP? signaling axis: current studies on B-cell lymphoma immunotherapy.

ABSTRACT: The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRP?. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRP? significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRP? pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRP? in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRP? axis, which yield insights into the immunotherapy of B-cell lymphoma.

SUBMITTER: Zhang J 

PROVIDER: S-EPMC6259379 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature